12h
Zacks.com on MSNBiotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug ApprovalIt was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...
Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results